275 related articles for article (PubMed ID: 38094656)
1. Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study.
Wang H; Wen T; Zhu W; Li K; Gong X; Li Z
Mater Today Bio; 2024 Feb; 24():100905. PubMed ID: 38094656
[TBL] [Abstract][Full Text] [Related]
2. Microfluidic Organs-on-a-Chip for Modeling Human Infectious Diseases.
Wang Y; Wang P; Qin J
Acc Chem Res; 2021 Sep; 54(18):3550-3562. PubMed ID: 34459199
[TBL] [Abstract][Full Text] [Related]
3. Advances of microfluidic lung chips for assessing atmospheric pollutants exposure.
Wang H; Yin F; Li Z; Su W; Li D
Environ Int; 2023 Feb; 172():107801. PubMed ID: 36774736
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic lung-on-a-chip to model virus infection and drug evaluation.
Tan J; Guo Q; Tian L; Pei Z; Li D; Wu M; Zhang J; Gao X
Eur J Pharm Sci; 2023 Jan; 180():106329. PubMed ID: 36375766
[TBL] [Abstract][Full Text] [Related]
5. Human Organoids and Organs-on-Chips for Addressing COVID-19 Challenges.
Wang Y; Wang P; Qin J
Adv Sci (Weinh); 2022 Apr; 9(10):e2105187. PubMed ID: 35107217
[TBL] [Abstract][Full Text] [Related]
6. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
8. A microfluidic lung-on-a-chip based on biomimetic hydrogel membrane.
Shen C; Yang H; She W; Meng Q
Biotechnol Bioeng; 2023 Jul; 120(7):2027-2038. PubMed ID: 37195718
[TBL] [Abstract][Full Text] [Related]
9. Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): The Immunopathology of a SARS-CoV2 Infection.
Tsai SF; Lu KY; Chuang HM; Liu CA
Cell Transplant; 2021; 30():963689721993769. PubMed ID: 33840257
[TBL] [Abstract][Full Text] [Related]
10. [Applications of separation technology in novel coronavirus research, epidemic prevention and detection].
Li L; Zhu C; Zhao X; Qu F
Se Pu; 2021 Jul; 39(7):679-685. PubMed ID: 34227364
[TBL] [Abstract][Full Text] [Related]
11. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.
Ekanger CT; Zhou F; Bohan D; Lotsberg ML; Ramnefjell M; Hoareau L; Røsland GV; Lu N; Aanerud M; Gärtner F; Salminen PR; Bentsen M; Halvorsen T; Ræder H; Akslen LA; Langeland N; Cox R; Maury W; Stuhr LEB; Lorens JB; Engelsen AST
Front Cell Infect Microbiol; 2022; 12():841447. PubMed ID: 35360113
[TBL] [Abstract][Full Text] [Related]
12. [Advances of using microfluidic chips for research and diagnosis of pulmonary inflammatory diseases].
Xia T; Zou W; Liu J
Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3905-3914. PubMed ID: 34841794
[TBL] [Abstract][Full Text] [Related]
13. Murine-β-coronavirus-induced neuropathogenesis sheds light on CNS pathobiology of SARS-CoV2.
Chakravarty D; Das Sarma J
J Neurovirol; 2021 Apr; 27(2):197-216. PubMed ID: 33547593
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal lung support technologies - bridge to recovery and bridge to lung transplantation in adult patients: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(5):1-47. PubMed ID: 23074408
[TBL] [Abstract][Full Text] [Related]
15. Organs-on-chips technologies - A guide from disease models to opportunities for drug development.
Monteduro AG; Rizzato S; Caragnano G; Trapani A; Giannelli G; Maruccio G
Biosens Bioelectron; 2023 Jul; 231():115271. PubMed ID: 37060819
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
17. RNAi-mediated siRNA sequences to combat the COVID-19 pandemic with the inhibition of SARS-CoV2.
Saadat KASM
Gene Rep; 2022 Mar; 26():101512. PubMed ID: 35071824
[TBL] [Abstract][Full Text] [Related]
18. 3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics.
Plebani R; Bai H; Si L; Li J; Zhang C; Romano M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077471
[TBL] [Abstract][Full Text] [Related]
19. Human-Based Advanced
Kiener M; Roldan N; Machahua C; Sengupta A; Geiser T; Guenat OT; Funke-Chambour M; Hobi N; Kruithof-de Julio M
Front Med (Lausanne); 2021; 8():644678. PubMed ID: 34026781
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury.
Guo J; Wei X; Li Q; Li L; Yang Z; Shi Y; Qin Y; Zhang X; Wang X; Zhi X; Meng D
J Cell Physiol; 2020 Dec; 235(12):9884-9894. PubMed ID: 32510598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
